Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 3/20 | 0.52 |
| ▸ | MAOB known ✓ | P27338 | 3/20 | 0.48 |
| ▸ | CYP19A1 known ✓ | P11511 | 2/20 | 0.46 |
| ▸ | MAOA known ✓ | P21397 | 2/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.59 |
| ▸ | PAM | P19021 | 1/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9595036 | 1.00 | IDO1 (0.59) | IDO1HTR2APAMMAOBCYP19A1 | |
| Hydrochloric Acid SCHEMBL6314436 | 1.00 | IDO1 (0.59) | IDO1HTR2APAMMAOBCYP19A1 | |
| SCHEMBL10422962 | 0.97 | IDO1 (0.58) | IDO1HTR2APAMMAOBCYP19A1 | |
| SCHEMBL1872 | 0.97 | IDO1 (0.58) | IDO1HTR2APAMMAOBCYP19A1 | |
| SCHEMBL460826 | 0.97 | IDO1 (0.58) | IDO1HTR2APAMMAOBCYP19A1 | |
| Calcium SCHEMBL253355 | 0.95 | IDO1 (0.56) | IDO1HTR2APAMMAOBCYP19A1 | |
| Water SCHEMBL5430579 | 0.95 | IDO1 (0.56) | IDO1HTR2APAMMAOBCYP19A1 | |
| Iodide SCHEMBL28732828 | 0.95 | IDO1 (0.56) | IDO1HTR2APAMMAOBCYP19A1 | |
| Bromide SCHEMBL28536146 | 0.95 | IDO1 (0.56) | IDO1HTR2APAMMAOBCYP19A1 | |
| Ethylenediamine SCHEMBL9321899 | 0.93 | IDO1 (0.54) | IDO1HTR2APAMMAOBCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109870583-B | Metabolites associated with acute pancreatitis and uses thereof | 德阳市人民医院 | 2020-03-06 | — | — | CN | claimed |
| CN-109870583-B | Metabolites associated with acute pancreatitis and uses thereof | 德阳市人民医院 | 2020-03-06 | — | — | CN | disclosed |
| CN-109870583-B | Metabolites associated with acute pancreatitis and uses thereof | 德阳市人民医院 | 2020-03-06 | — | — | CN | disclosed |
| US-6946460-B2 | Azole or triazole derivatives, method for preparing same and use thereof as fungicides | AVENTIS PHARMA S.A. (FR) | 2005-09-20 | — | — | US | disclosed |
| US-20050043540-A1 | Novel azole or triazole derivatives, method for preparing same and use thereof as fungicides | AVENTIS PHARMA S. A, (FR) | 2005-02-24 | — | — | US | disclosed |
| CN-1537105-A | Quinazolines useful as MMP-13 inhibitors | ��������ʲ��������ι�˾ | 2004-10-13 | — | — | CN | disclosed |
| EP-1368324-A1 | QUINAZOLINES AS MMP-13 INHIBITORS | Warner-Lambert Company LLC (US) | 2003-12-10 | — | — | EP | disclosed |
| US-20020193377-A1 | Quinazolines as MMP-13 inhibitors | ANDRIANJARA CHARLES (FR) | 2002-12-19 | — | — | US | disclosed |
| WO-2002064572-A1 | QUINAZOLINES AS MMP-13 INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | disclosed |
| US-6395730-B1 | CARDIOVASCULAR DISORDERS | ICAGEN, INC. | 2002-05-28 | — | — | US | disclosed |
| US-6339089-B2 | ANTIHYPOXIC AGENTS; CHRONIC OBSTRUCTIVE PULMONARY DISEASE; VASOCONSTRICTION; REDUCES BLOOD PARTIAL PRESSURE OF CARBON DIOXIDE; RESPIRATORY DISORDERS; UNDER OXYGEN INHALATION TREATMENT | FUJIREBIO INC. (JP) | 2002-01-15 | — | — | US | disclosed |
| US-20010006969-A1 | PYRIMIDINE NUCLEUS-CONTAINING COMPOUND AND A MEDICAMENT CONTAINING THE SAME FOR A BLOOD OXYGEN PARTIAL PRESSURE AMELIORATION, AND A METHOD FOR PREPARING THE SAME | FUJIREBIO INC. (FUJIREBIO KABUSHIKI KAISHA) (JP) | 2001-07-05 | — | — | US | disclosed |
| EP-1082315-A1 | POTASSIUM CHANNEL INHIBITORS | Icagen, Inc. (US) | 2001-03-14 | — | — | EP | disclosed |
| US-6174908-B1 | TREATING DISEASE, CONDITION, OR DISORDER WHICH RESPONDS TO INHIBITION OF POTASSIUM CHANNEL FUNCTION BY ADMINISTERING THIAZOLIDONE OR METATHIAZONONE COMPOUND, ITS SALT, AMIDE, ESTER, COMPLEX, CHELATE, HYDRATE, STEREOISOMER, METABOLITE | ICAGEN, INC. | 2001-01-16 | — | — | US | disclosed |
| US-6033853-A | Nucleotide sequence detection with signal amplification | BIO MERIEUX (FR) | 2000-03-07 | — | — | US | disclosed |
| WO-1999062891-A1 | POTASSIUM CHANNEL INHIBITORS | ICAGEN, INC. (US) | 1999-12-09 | — | — | WO | disclosed |
| EP-0899263-A2 | Fused pyrimidine derivatives and medicaments thereof for a blood oxygen partial pressure amelioration | Fujirebio Inc. (JP) | 1999-03-03 | — | — | EP | disclosed |
| US-5576140-A | MODIFIED POLYVINYL ACETAL | FUJI PHOTO FILM CO., LTD. (JP) | 1996-11-19 | — | — | US | disclosed |
| US-5196454-A | METHOD OF TREATING DISORDERS OF THE DOPAMINERGIC SYSTEMS USING 2,5-DIAMINOTETRALINES | BOEHRINGER INGELHEIM KG (DE) | 1993-03-23 | — | — | US | disclosed |
| US-4239908-A | N-aralkenyl-N'-cyano-N\"-(heterocyclylthioalkyl)-guanidines | G.D. SEARLE & CO. (US) | 1980-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010006969-A1 | PYRIMIDINE NUCLEUS-CONTAINING COMPOUND AND A MEDICAMENT CONTAINING THE SAME FOR A BLOOD OXYGEN PARTIAL PRESSURE AMELIORATION, AND A METHOD FOR PREPARING THE SAME | CYP11B2, CYP11B1, OAT | HTR2A 2709/4885MAOB 407/4885CYP19A1 1540/4885 |
| US-20020193377-A1 | Quinazolines as MMP-13 inhibitors | MMP13, MMP9, MMP3 | HTR2A 740/4885MAOB 163/4885CYP19A1 749/4885 |
| US-20050043540-A1 | Novel azole or triazole derivatives, method for preparing same and use thereof as fungicides | CYP1A2, CYP1B1, CYP21A2 | HTR2A 4086/4885MAOB 1239/4885CYP19A1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.